1034924-06-5 Usage
Uses
Used in Pharmaceutical Research and Development:
(2-Methylpyrimidin-5-yl)boronic acid is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its boronic acid functional group enables the formation of boronate, which is crucial in many chemical reactions, making it a valuable component in the development of new drugs and therapeutic agents.
Used in Chemical Reactions:
In the field of organic chemistry, (2-Methylpyrimidin-5-yl)boronic acid is used as a reagent in various chemical reactions. Its ability to form boronate with diols allows for the creation of new chemical bonds and the synthesis of complex molecules, which can be further utilized in the development of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Material Science:
(2-Methylpyrimidin-5-yl)boronic acid can also be used in material science applications, where its boronic acid functional group can be employed to create new materials with unique properties. These materials could potentially be used in the development of advanced materials for electronics, coatings, or other industrial applications.
Check Digit Verification of cas no
The CAS Registry Mumber 1034924-06-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,3,4,9,2 and 4 respectively; the second part has 2 digits, 0 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1034924-06:
(9*1)+(8*0)+(7*3)+(6*4)+(5*9)+(4*2)+(3*4)+(2*0)+(1*6)=125
125 % 10 = 5
So 1034924-06-5 is a valid CAS Registry Number.
1034924-06-5Relevant articles and documents
PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA
-
Page/Page column 57-58, (2017/11/01)
The instant invention provides compounds of formula (I) which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflamation, asthma, COPD and cancer.
PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA
-
Page/Page column 66; 67, (2014/06/11)
The instant invention provides compounds of formula I which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflamation, asthma, COPD and cancer.